Literature DB >> 27239171

Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy.

Christoph Domschke1, Andreas Schneeweiss1, Stefan Stefanovic1, Markus Wallwiener1, Joerg Heil1, Joachim Rom1, Christof Sohn1, Philipp Beckhove2, Florian Schuetz1.   

Abstract

More recently, immunotherapy has emerged as a novel potentially effective therapeutic option also for solid malignancies such as breast cancer (BC). Relevant approaches, however, are determined by the 2 main elements of cancer immunoediting - the elimination of nascent transformed cells by immunosurveillance on the one hand and tumor immune escape on the other hand. Correspondingly, we here review the role of the various cellular immune players within the host-protective system and dissect the mechanisms of immune evasion leading to tumor progression. If the immune balance of disseminated BC cell dormancy (equilibrium phase) is lost, distant metastatic relapse may occur. The relevant cellular antitumor responses and translational immunotherapeutic options will also be discussed in terms of clinical benefit and future directions in BC management.

Entities:  

Keywords:  Breast cancer; Cellular immunity; Immune escape; Immunoediting; Immunosurveillance; Immunotherapy

Year:  2016        PMID: 27239171      PMCID: PMC4881254          DOI: 10.1159/000446061

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  81 in total

1.  Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells.

Authors:  Irina B Mazo; Marek Honczarenko; Harry Leung; Lois L Cavanagh; Roberto Bonasio; Wolfgang Weninger; Katharina Engelke; Lijun Xia; Rodger P McEver; Pandelakis A Koni; Leslie E Silberstein; Ulrich H von Andrian
Journal:  Immunity       Date:  2005-02       Impact factor: 31.745

2.  Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Authors:  Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

3.  Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study.

Authors:  Florian Schuetz; Katrin Ehlert; Yingzi Ge; Andreas Schneeweiss; Joachim Rom; Natalija Inzkirweli; Christoph Sohn; Volker Schirrmacher; Philipp Beckhove
Journal:  Cancer Immunol Immunother       Date:  2008-11-08       Impact factor: 6.968

Review 4.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

5.  Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells.

Authors:  Eric Yvon; Michele Del Vecchio; Barbara Savoldo; Valentina Hoyos; Aurélie Dutour; Andrea Anichini; Gianpietro Dotti; Malcolm K Brenner
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

6.  Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.

Authors:  Philipp Koehler; Patrick Schmidt; Andreas A Hombach; Michael Hallek; Hinrich Abken
Journal:  Adv Hematol       Date:  2011-08-08

7.  Dendritic cell cancer vaccines: from the bench to the bedside.

Authors:  Tamar Katz; Irit Avivi; Noam Benyamini; Jacalyn Rosenblatt; David Avigan
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

8.  Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Hee Jin Lee; Jin-Young Seo; Jin-Hee Ahn; Sei-Hyun Ahn; Gyungyub Gong
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

9.  Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.

Authors:  Eva Ellebaek; Trine Zeeberg Iversen; Niels Junker; Marco Donia; Lotte Engell-Noerregaard; Özcan Met; Lisbet Rosenkrantz Hölmich; Rikke Sick Andersen; Sine Reker Hadrup; Mads Hald Andersen; Per thor Straten; Inge Marie Svane
Journal:  J Transl Med       Date:  2012-08-21       Impact factor: 5.531

10.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

View more
  11 in total

1.  Immunological Mechanisms in Breast Cancer - from Bench to Bedside.

Authors:  Carsten Denkert; Florian Schütz
Journal:  Breast Care (Basel)       Date:  2016-04-27       Impact factor: 2.860

2.  CD8+ cytotoxic and FoxP3+ regulatory T lymphocytes serve as prognostic factors in breast cancer.

Authors:  Gong-Ling Peng; Liang Li; Ya-Wen Guo; Pan Yu; Xing-Jie Yin; Shan Wang; Chun-Ping Liu
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

3.  Increased Tumour Infiltration of CD4+ and CD8+ T-Lymphocytes in Patients with Triple Negative Breast Cancer Suggests Susceptibility to Immune Therapy

Authors:  Bushra Sikandar; Muhammad Asif Qureshi; Saima Naseem; Saeed Khan; Talat Mirza
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

4.  Tumacrophage: macrophages transformed into tumor stem-like cells by virulent genetic material from tumor cells.

Authors:  Yizhuang Zhang; Na Zhou; Xiuyan Yu; Xuehui Zhang; Shanxin Li; Zhen Lei; Ruobi Hu; Hui Li; Yiqing Mao; Xi Wang; Jinshu Zhang; Yuan Li; Hongyan Guo; David M Irwin; Gang Niu; Huanran Tan
Journal:  Oncotarget       Date:  2017-07-18

Review 5.  Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research.

Authors:  Bárbara Pinto; Ana C Henriques; Patrícia M A Silva; Hassan Bousbaa
Journal:  Pharmaceutics       Date:  2020-12-06       Impact factor: 6.321

6.  Follistatin-like 1 deficiency impairs T cell development to promote lung metastasis of triple negative breast cancer.

Authors:  Jie Ma; Ying Yang; Lulu Wang; Xiaowei Jia; Tao Lu; Yiyan Zeng; Li Liu; Yan Gao
Journal:  Aging (Albany NY)       Date:  2021-02-26       Impact factor: 5.682

7.  TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes.

Authors:  Franziska Würfel; Ramona Erber; Hanna Huebner; Alexander Hein; Michael P Lux; Sebastian Jud; Anita Kremer; Hannah Kranich; Andreas Mackensen; Lothar Häberle; Carolin C Hack; Claudia Rauh; Marius Wunderle; Paul Gaß; Shahrooz Rabizadeh; Anna-Lisa Brandl; Hanna Langemann; Bernhard Volz; Naiba Nabieva; Rüdiger Schulz-Wendtland; Diana Dudziak; Matthias W Beckmann; Arndt Hartmann; Peter A Fasching; Matthias Rübner
Journal:  Breast Care (Basel)       Date:  2018-02-15       Impact factor: 2.860

Review 8.  Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors.

Authors:  Jinjing Xu; Yali Wang; Jing Shi; Juan Liu; Qingguo Li; Longzhou Chen
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 3.111

9.  Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Authors:  Li Chen; Xiangyi Kong; Shaolong Huang; Zhaohui Su; Mengliu Zhu; Yi Fang; Lin Zhang; Xingrui Li; Jing Wang
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

Review 10.  Assessing the Future of Solid Tumor Immunotherapy.

Authors:  Prajna Guha; Kara R Heatherton; Kyle P O'Connell; Ian S Alexander; Steven C Katz
Journal:  Biomedicines       Date:  2022-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.